Tokai Pharmaceuticals Appoints Lee Kalowski as Chief Financial Officer

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Tokai Pharmaceuticals, Inc., a biopharmaceutical company focused on developing novel therapies for prostate cancer and other hormonally-driven diseases, today announced the appointment of Lee Kalowski as chief financial officer, effective immediately. Mr. Kalowski brings more than a decade of experience in the life sciences sector to Tokai.

"We are delighted to welcome Lee to Tokai's management team. Lee brings finance, strategy and industry expertise to Tokai as well as a deep knowledge of the prostate cancer therapeutics market"
"We are delighted to welcome Lee to Tokai's management team. Lee brings finance, strategy and industry expertise to Tokai as well as a deep knowledge of the prostate cancer therapeutics market," stated Jodie Morrison, president and chief executive officer. "Overseeing financial operations at Tokai, we expect Lee will be instrumental to the team as we work to bring our lead product candidate, galeterone, into Phase 3 development and advance our Androgen Receptor Degrading Agents (ARDA) platform."

Prior to joining Tokai, Mr. Kalowski served as vice president, global biotechnology equity research at Credit Suisse. In this role, Mr. Kalowski served as a senior research analyst covering the biotechnology industry, including companies in the prostate cancer therapeutic area. Prior to joining Credit Suisse, he worked in mergers and acquisitions in the pharmaceutical division of Johnson & Johnson, and in global pharmaceutical equity research at Sanford C. Bernstein and Prudential Equity Group. Mr. Kalowski holds a B.A. in biology and economics from Union College and an M.B.A. in finance and health care management from the Wharton School, University of Pennsylvania.

"This is an exciting time to be joining Tokai with the company finalizing its plans for a Phase 3 trial of galeterone," said Mr. Kalowski. "I'm looking forward to working with the Tokai team to help advance this product and make a meaningful difference to patients."

About Galeterone

Galeterone is a highly selective, multi-targeted, oral small molecule drug candidate being developed for the treatment of castration-resistant prostate cancer that acts by actively disrupting androgen receptor (AR) signaling, the key driver of prostate cancer growth, via multiple mechanisms of action. Galeterone combines the mechanisms of action of CYP17 inhibition and androgen receptor antagonism with an additional mechanism of androgen receptor degradation. Current available therapies disrupt the pathway at a single point. To Tokai's knowledge, galeterone is the only drug candidate in clinical trials that disrupts the pathway at multiple points.

About Tokai Pharmaceuticals

Tokai Pharmaceuticals is a biopharmaceutical company focused on developing novel therapies for prostate cancer and other hormonally-driven diseases. The company's lead drug candidate, galeterone, is a highly selective, multi-targeted, oral small molecule drug candidate being developed for the treatment of patients with castration-resistant prostate cancer. The Company's ARDA drug discovery program is focused on the identification and evaluation of compounds with potent androgen receptor degradation activity targeted to patients with androgen receptor signaling diseases, including prostate cancer. Based in Cambridge, Massachusetts, Tokai is backed by Apple Tree Partners, Novartis Venture Funds, Satter Investment Management, as well as other investors. For more information on the company and galeterone, please visit www.tokaipharma.com.

Contacts

Pure Communications, Inc.
Sheryl Seapy, 949-903-4750

Suggested Articles

In this week's EuroBiotech Report, Sitryx inks Lilly deal, Genfit downplays COVID-19 impact on NASH data and Gilead tests remdesivir in U.K.

Amgen and new partner Adaptive Biotechnologies are the latest pharma-biotech duo joining forces against the pandemic.

In our EuroBiotech roundup this week, AM-Pharma raises €23 million, Nordic Nanovector makes cuts and Neurimmune, Ethris plan COVID-19 trial.